Meeting on the Med 2021 | A non-gene edited approach to allogeneic CAR-T development

Filippo Petti, CEO/CFO, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the benefits of using a non-gene edited approach for the development of single-vector, allogeneic CAR-T cancer therapies. Preliminary data from the ongoing Phase I alloSHRINK study (NCT03692429) in patients with colorectal cancer treated with CYAD-101, a natural killer group 2D (NKG2D) CAR-T candidate encoding the T cell receptor inhibitory molecule (TIM), has highlighted the potential of this approach. He also introduces the recently launched Phase I IMMUNICY-1 study (NCT04613557) investigating CYAD-211, a short hairpin RNA (shRNA)-based CAR T therapy, in patients with multiple myeloma. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.